These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
439 related articles for article (PubMed ID: 29588392)
21. FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. Hirakata T; Fujii T; Kurozumi S; Katayama A; Honda C; Yanai K; Tokuda S; Nakazawa Y; Obayashi S; Yajima R; Kaira K; Oyama T; Shirabe K Breast Cancer Res Treat; 2020 Jun; 181(2):331-338. PubMed ID: 32253685 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy. Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959 [TBL] [Abstract][Full Text] [Related]
23. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929 [TBL] [Abstract][Full Text] [Related]
25. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy. Liang Y; Yu M; Zhou C; Zhu X Diagn Pathol; 2020 Jun; 15(1):67. PubMed ID: 32493336 [TBL] [Abstract][Full Text] [Related]
26. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival. Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015 [TBL] [Abstract][Full Text] [Related]
27. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145 [TBL] [Abstract][Full Text] [Related]
28. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer. Rozenblit M; Blenman K; Harigopal M; Reisenbichler E; Singh K; Qing T; Ibrahim E; Ramkissoon S; Asmelash S; Lin HK; Roberts M; Ross J; Huang RSP; Pusztai L Breast Cancer Res Treat; 2022 Nov; 196(1):221-227. PubMed ID: 36028784 [TBL] [Abstract][Full Text] [Related]
29. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569 [No Abstract] [Full Text] [Related]
30. Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer. Wang H; Ding XH; Liu CL; Xiao Y; Shui RH; Li YP; Chen C; Yang WT; Liu S; Chen CS; Shao ZM; Jiang YZ J Natl Cancer Inst; 2023 Dec; 115(12):1586-1596. PubMed ID: 37549066 [TBL] [Abstract][Full Text] [Related]
31. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467 [No Abstract] [Full Text] [Related]
32. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy. Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889 [TBL] [Abstract][Full Text] [Related]
33. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer. Horimoto Y; Thinzar Hlaing M; Saeki H; Kitano S; Nakai K; Sasaki R; Kurisaki-Arakawa A; Arakawa A; Otsuji N; Matsuoka S; Tokuda E; Arai M; Saito M Cancer Sci; 2020 Jul; 111(7):2647-2654. PubMed ID: 32449246 [TBL] [Abstract][Full Text] [Related]
34. The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer. Çetin K; Kökten Ş; Sarıkamış B; Yıldırım S; Gökçe ON; Barışık NÖ; Kılıç Ü Breast Cancer Res Treat; 2024 May; 205(1):17-27. PubMed ID: 38273215 [TBL] [Abstract][Full Text] [Related]
35. Assessing the relationship between tumor-infiltrating lymphocytes and PD-L1 expression in triple negative breast cancer: Identifying optimal TILs cut-off value for pathologic reporting. Suwannaphoom K; Soontornsit S; Wiwatwarayos K; Seneetuntigul P; Julimasart P Ann Diagn Pathol; 2024 Jun; 70():152294. PubMed ID: 38513466 [TBL] [Abstract][Full Text] [Related]
36. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Zhang L; Wang XI; Ding J; Sun Q; Zhang S Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176 [TBL] [Abstract][Full Text] [Related]
37. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786 [TBL] [Abstract][Full Text] [Related]
38. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers. Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063 [TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219 [TBL] [Abstract][Full Text] [Related]
40. Tumor-infiltrating lymphocytes, PD-L1, and MMR-deficiency combined characterization may identify subgroups of rectal cancer patients who would benefit from immunotherapy. Giatromanolaki A; Kavazis C; Gkegka AG; Kouroupi M; Tsaroucha A; Pitiakoudis M; Koukourakis MI Immunobiology; 2023 Nov; 228(6):152756. PubMed ID: 38860277 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]